Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis

M Galli, Spinello Antinori, F Atzeni, Luca Meroni, A Riva, C Scirè, F Adorni, L Quartuccio, Marco Sebastiani, P Airò, Laura Bazzichi, F Cristini, V Del Bono, A Manfredi, O Viapiana, F De Rosa, Ennio Giulio Favalli, Enzo Petrelli, C Salvarani, M GovoniSilvia Corcione, R Scrivo, Loredana Sarmati, A Lazzarin, W Grassi, Claudio Maria Mastroianni, Giovanni B. Gaeta, Gianfranco Ferraccioli, M Cutolo, S De Vita, Giovanni Lapadula, M Matucci-Cerinic, O Armignacco, P Sarzi-Puttini

Research output: Contribution to journalArticle

Abstract

Often life-threatening pulmonary fungal infections (PFIs) can occur in patients with rheumatoid arthritis (RA) receiving disease-modifying anti-rheumatic drugs (DMARDs). Most of the data concerning PFIs in RA patients come from case reports and retrospective case series. Of the ve most widely described PFIs, Pneumocystis jirovecii pneumonia (PJP) has rarely been seen outside Japan, pulmonary cryptococcosis has been diagnosed in only a small number of patients worldwide, pulmonary coccidioidomycosis has almost only been observed in endemic areas, the limited number of cases of pulmonary histoplasmosis have mainly occurred in the USA, and the rare cases of invasive pulmonary aspergillosis have only been encountered in leukopenic patients. Many aspects of the prophylaxis, diagnosis and treatment of PFIs in RA patients remain to be defined, as does the role of each DMARD in increasing the risk of infection, and the possibility of resuming biological and non-biological DMARD treatment after the infection has been cured. The recommendations for the management of PFIs described in this paper are the product of a consensus procedure promoted by the Italian group for the Study and Management of Infections in Patients with Rheumatic Diseases (the ISMIR group).
Original languageEnglish
Pages (from-to)1018-1028
Number of pages11
JournalClinical and Experimental Rheumatology
Volume35
Issue number6
Publication statusPublished - 2017

Fingerprint

Fungal Lung Diseases
Rheumatoid Arthritis
Antirheumatic Agents
Lung
Infection
Invasive Pulmonary Aspergillosis
Coccidioidomycosis
Pneumocystis carinii
Cryptococcosis
Histoplasmosis
Pneumocystis Pneumonia
Rheumatic Diseases
Japan
Therapeutics

Cite this

Galli, M., Antinori, S., Atzeni, F., Meroni, L., Riva, A., Scirè, C., ... Sarzi-Puttini, P. (2017). Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 35(6), 1018-1028.

Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. / Galli, M; Antinori, Spinello; Atzeni, F; Meroni, Luca; Riva, A; Scirè, C; Adorni, F; Quartuccio, L; Sebastiani, Marco; Airò, P; Bazzichi, Laura; Cristini, F; Del Bono, V; Manfredi, A; Viapiana, O; De Rosa, F; Favalli, Ennio Giulio; Petrelli, Enzo; Salvarani, C; Govoni, M; Corcione, Silvia; Scrivo, R; Sarmati, Loredana; Lazzarin, A; Grassi, W; Mastroianni, Claudio Maria; Gaeta, Giovanni B.; Ferraccioli, Gianfranco; Cutolo, M; De Vita, S; Lapadula, Giovanni; Matucci-Cerinic, M; Armignacco, O; Sarzi-Puttini, P.

In: Clinical and Experimental Rheumatology, Vol. 35, No. 6, 2017, p. 1018-1028.

Research output: Contribution to journalArticle

Galli, M, Antinori, S, Atzeni, F, Meroni, L, Riva, A, Scirè, C, Adorni, F, Quartuccio, L, Sebastiani, M, Airò, P, Bazzichi, L, Cristini, F, Del Bono, V, Manfredi, A, Viapiana, O, De Rosa, F, Favalli, EG, Petrelli, E, Salvarani, C, Govoni, M, Corcione, S, Scrivo, R, Sarmati, L, Lazzarin, A, Grassi, W, Mastroianni, CM, Gaeta, GB, Ferraccioli, G, Cutolo, M, De Vita, S, Lapadula, G, Matucci-Cerinic, M, Armignacco, O & Sarzi-Puttini, P 2017, 'Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis', Clinical and Experimental Rheumatology, vol. 35, no. 6, pp. 1018-1028.
Galli, M ; Antinori, Spinello ; Atzeni, F ; Meroni, Luca ; Riva, A ; Scirè, C ; Adorni, F ; Quartuccio, L ; Sebastiani, Marco ; Airò, P ; Bazzichi, Laura ; Cristini, F ; Del Bono, V ; Manfredi, A ; Viapiana, O ; De Rosa, F ; Favalli, Ennio Giulio ; Petrelli, Enzo ; Salvarani, C ; Govoni, M ; Corcione, Silvia ; Scrivo, R ; Sarmati, Loredana ; Lazzarin, A ; Grassi, W ; Mastroianni, Claudio Maria ; Gaeta, Giovanni B. ; Ferraccioli, Gianfranco ; Cutolo, M ; De Vita, S ; Lapadula, Giovanni ; Matucci-Cerinic, M ; Armignacco, O ; Sarzi-Puttini, P. / Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. In: Clinical and Experimental Rheumatology. 2017 ; Vol. 35, No. 6. pp. 1018-1028.
@article{47195feb2da04494b46479bf2f3a3964,
title = "Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis",
abstract = "Often life-threatening pulmonary fungal infections (PFIs) can occur in patients with rheumatoid arthritis (RA) receiving disease-modifying anti-rheumatic drugs (DMARDs). Most of the data concerning PFIs in RA patients come from case reports and retrospective case series. Of the ve most widely described PFIs, Pneumocystis jirovecii pneumonia (PJP) has rarely been seen outside Japan, pulmonary cryptococcosis has been diagnosed in only a small number of patients worldwide, pulmonary coccidioidomycosis has almost only been observed in endemic areas, the limited number of cases of pulmonary histoplasmosis have mainly occurred in the USA, and the rare cases of invasive pulmonary aspergillosis have only been encountered in leukopenic patients. Many aspects of the prophylaxis, diagnosis and treatment of PFIs in RA patients remain to be defined, as does the role of each DMARD in increasing the risk of infection, and the possibility of resuming biological and non-biological DMARD treatment after the infection has been cured. The recommendations for the management of PFIs described in this paper are the product of a consensus procedure promoted by the Italian group for the Study and Management of Infections in Patients with Rheumatic Diseases (the ISMIR group).",
author = "M Galli and Spinello Antinori and F Atzeni and Luca Meroni and A Riva and C Scir{\`e} and F Adorni and L Quartuccio and Marco Sebastiani and P Air{\`o} and Laura Bazzichi and F Cristini and {Del Bono}, V and A Manfredi and O Viapiana and {De Rosa}, F and Favalli, {Ennio Giulio} and Enzo Petrelli and C Salvarani and M Govoni and Silvia Corcione and R Scrivo and Loredana Sarmati and A Lazzarin and W Grassi and Mastroianni, {Claudio Maria} and Gaeta, {Giovanni B.} and Gianfranco Ferraccioli and M Cutolo and {De Vita}, S and Giovanni Lapadula and M Matucci-Cerinic and O Armignacco and P Sarzi-Puttini",
year = "2017",
language = "English",
volume = "35",
pages = "1018--1028",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "6",

}

TY - JOUR

T1 - Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis

AU - Galli, M

AU - Antinori, Spinello

AU - Atzeni, F

AU - Meroni, Luca

AU - Riva, A

AU - Scirè, C

AU - Adorni, F

AU - Quartuccio, L

AU - Sebastiani, Marco

AU - Airò, P

AU - Bazzichi, Laura

AU - Cristini, F

AU - Del Bono, V

AU - Manfredi, A

AU - Viapiana, O

AU - De Rosa, F

AU - Favalli, Ennio Giulio

AU - Petrelli, Enzo

AU - Salvarani, C

AU - Govoni, M

AU - Corcione, Silvia

AU - Scrivo, R

AU - Sarmati, Loredana

AU - Lazzarin, A

AU - Grassi, W

AU - Mastroianni, Claudio Maria

AU - Gaeta, Giovanni B.

AU - Ferraccioli, Gianfranco

AU - Cutolo, M

AU - De Vita, S

AU - Lapadula, Giovanni

AU - Matucci-Cerinic, M

AU - Armignacco, O

AU - Sarzi-Puttini, P

PY - 2017

Y1 - 2017

N2 - Often life-threatening pulmonary fungal infections (PFIs) can occur in patients with rheumatoid arthritis (RA) receiving disease-modifying anti-rheumatic drugs (DMARDs). Most of the data concerning PFIs in RA patients come from case reports and retrospective case series. Of the ve most widely described PFIs, Pneumocystis jirovecii pneumonia (PJP) has rarely been seen outside Japan, pulmonary cryptococcosis has been diagnosed in only a small number of patients worldwide, pulmonary coccidioidomycosis has almost only been observed in endemic areas, the limited number of cases of pulmonary histoplasmosis have mainly occurred in the USA, and the rare cases of invasive pulmonary aspergillosis have only been encountered in leukopenic patients. Many aspects of the prophylaxis, diagnosis and treatment of PFIs in RA patients remain to be defined, as does the role of each DMARD in increasing the risk of infection, and the possibility of resuming biological and non-biological DMARD treatment after the infection has been cured. The recommendations for the management of PFIs described in this paper are the product of a consensus procedure promoted by the Italian group for the Study and Management of Infections in Patients with Rheumatic Diseases (the ISMIR group).

AB - Often life-threatening pulmonary fungal infections (PFIs) can occur in patients with rheumatoid arthritis (RA) receiving disease-modifying anti-rheumatic drugs (DMARDs). Most of the data concerning PFIs in RA patients come from case reports and retrospective case series. Of the ve most widely described PFIs, Pneumocystis jirovecii pneumonia (PJP) has rarely been seen outside Japan, pulmonary cryptococcosis has been diagnosed in only a small number of patients worldwide, pulmonary coccidioidomycosis has almost only been observed in endemic areas, the limited number of cases of pulmonary histoplasmosis have mainly occurred in the USA, and the rare cases of invasive pulmonary aspergillosis have only been encountered in leukopenic patients. Many aspects of the prophylaxis, diagnosis and treatment of PFIs in RA patients remain to be defined, as does the role of each DMARD in increasing the risk of infection, and the possibility of resuming biological and non-biological DMARD treatment after the infection has been cured. The recommendations for the management of PFIs described in this paper are the product of a consensus procedure promoted by the Italian group for the Study and Management of Infections in Patients with Rheumatic Diseases (the ISMIR group).

M3 - Article

VL - 35

SP - 1018

EP - 1028

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 6

ER -